Ro

Healthcare

Founded: 2017

Last Round Valuation: $7.19B

Ro, headquartered in New York, NY, is a telehealth platform that offers a wide range of healthcare services and personalized treatment options. Their platform caters to various concerns, including erectile dysfunction, fertility, hair, and skin issues. Users can conveniently access medication delivery through the Ro platform. The company was founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Robert Schutz. By leveraging telehealth technology, Ro aims to make healthcare more accessible and convenient for individuals seeking treatment for their specific health needs. Through their digital platform, Ro provides a seamless experience for users to connect with healthcare professionals and receive personalized care from the comfort of their own homes.

Ro Overview:

Ro, founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Robert Schutz, is a prominent telehealth platform headquartered in New York, NY. The company's mission is to provide accessible and personalized healthcare solutions for a range of concerns, including erectile dysfunction, fertility, hair loss, and skin issues.

At the core of Ro's services is their telehealth platform, which enables individuals to connect with healthcare professionals remotely. Through this platform, users can discreetly and conveniently seek medical advice, obtain personalized treatment options, and receive necessary prescriptions without the need for in-person appointments.

Ro's approach to healthcare involves leveraging technology to break down barriers to access, allowing individuals to address sensitive health concerns with ease and privacy. By providing a user-friendly digital interface, Ro streamlines the process of receiving care, eliminating the traditional obstacles associated with scheduling appointments, traveling to clinics, and waiting in crowded waiting rooms.

One of the key areas Ro focuses on is the treatment of erectile dysfunction (ED). By offering a comprehensive telemedicine solution, Ro provides discreet consultations with licensed healthcare professionals who can diagnose and prescribe appropriate medication for ED. In addition, Ro offers medication delivery services, ensuring that individuals have convenient access to the prescribed treatments.

Ro also addresses fertility concerns through their telehealth platform. They provide consultations and personalized treatment options for couples and individuals seeking fertility support. By connecting patients with fertility specialists, Ro helps guide them through the journey of fertility evaluation, diagnosis, and treatment, offering personalized care and support along the way.

In addition to ED and fertility, Ro addresses hair loss and skin issues through their platform. They offer virtual consultations with healthcare professionals who can recommend appropriate treatments and provide prescriptions as needed. Ro's holistic approach to healthcare encompasses providing comprehensive solutions for individuals seeking to address these specific concerns.

Ro's commitment to patient care and safety is evident in their rigorous vetting process for healthcare professionals on their platform. All healthcare providers go through a thorough review and credentialing process to ensure high-quality care and adherence to industry standards.

Since its inception, Ro has experienced significant growth and has expanded its services to meet the evolving needs of its users. They continue to innovate in the telehealth space, leveraging technology to deliver accessible, personalized, and convenient healthcare solutions. Through their platform, Ro aims to empower individuals to take control of their health and well-being, providing them with the support they need to live healthier lives.

Founders:

  • Zachariah Reitano

  • Saman Rahmanian

  • Robert Schutz

Top Investors:

  • 3LAltimeter Capital

  • Baupost Group

  • Blue 9 Capital

  • BoxGroup

  • Canaan Partners

  • Chapter One Ventures

  • Dragoneer

  • Evolution VC Partners

  • FirstMark Capital

  • General Catalys

  • Initialized Capital Management

  • J Ventures

  • PROOF Fund

  • Radcliff

  • Rosecliff Venture Partners

  • Sand Hill Angels

  • Seven Seven Six

  • ShawSpring Partners

  • SignalFire

  • Sinai Ventures

  • Slow Ventures

  • TQ Ventures

  • The Chernin Group

  • Torch Capital

  • Tusk Ventures

Funding History:


Date Share Type Amount Raised Raised to Date Issue Price Post Money Valuation Key Investors
Feb 2022 Series D-1 $100MM $884.86MM $15.33 $7.19B ShawSpring Partners, General Catalyst, FirstMark Capital
Mar 2021 Series D $510MM $784.86MM $11.89 $5.25B General Catalyst, FirstMark Capital and TQ Ventures, SignalFire
Jul 2020 Series C-3 $40.6MM $192.92MM $3.26 $1.8B General Catalyst, FirstMark Capital, Torch
Jul 2020 Series C-2 $39.79MM $192.11MM $3.26 $1.8B General Catalyst, FirstMark Capital, Torch
Jul 2020 Series C-1 $42.15MM $194.48MM $4.08 $1.8B General Catalyst, FirstMark Capital, Torch
Jul 2020 Series B $85.54MM $152.32MM $1.49 $540.95MM FirstMark Capital, PROOF Fund, Canaan Partners
Sep 2019 Series A $19.95MM $23.1MM $0.45 $240.27MM FirstMark Capital, General Catalyst, Rosecliff Venture Partners
Sep 2019 Series A-1 $3.69MM $6.84MM $0.36 $240.27MM FirstMark Capital, General Catalyst, Rosecliff Venture Partners
Sep 2019 Series A-2 $39.99MM $43.14MM $0.79 $240.27MM FirstMark Capital, General Catalyst, Rosecliff Venture Partners
Aug 2017 Series Seed $3.15MM $3.15MM $0.10 $19.84MM General Catalyst

In the News: